By clicking "Allow All" you agree to the storing of cookies on your device to enhance site navigation,
analyse site usage and support us in providing free open access scientific content.
Rapid Novor Inc. is the world's leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing to access the producing cell line.
As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company's REmAb™ antibody protein sequencing service has allowed for the accurate sequencing of any given antibody proteins on a routine basis. The company's WILD™ service is the first commercially available service that can accurately distinguish the isomeric Isoleucine and Leucine using mass spectrometry.
Rapid Novor Inc's mission is to advance life science for better human health with next generation protein sequencing.
Rapid Novor First to Decode Polyclonal Antibodies Using Only Proteomics
Rapid Novor moves into a new state-of-the-art facility for next phase of growth
Artificial intelligence and polyclonal antibody sequencing redefine the future of antibody discovery
A World First: sequencing polyclonal antibodies using only proteomics
Ensuring 100% Accuracy in Antibody Protein Sequencing
A Single Platform to Sequence All Monoclonal Antibody Proteins
Deciphering Antibodies with Next-Generation Protein Sequencing Technology
Polyclonal Antibody Sequencing for the Next Generation Antibody Discovery
Review: Antibody Protein Sequence Analysis Using Mass Spectrometry